Stifel Nicolaus Lowers Zoetis (NYSE:ZTS) Price Target to $180.00

Zoetis (NYSE:ZTS - Get Free Report) had its price target cut by stock analysts at Stifel Nicolaus from $210.00 to $180.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a "buy" rating on the stock. Stifel Nicolaus' price target would suggest a potential upside of 9.97% from the stock's current price.

A number of other research firms have also recently issued reports on ZTS. Leerink Partners began coverage on Zoetis in a report on Monday, December 2nd. They issued an "outperform" rating and a $215.00 price objective for the company. UBS Group began coverage on shares of Zoetis in a research note on Monday, December 9th. They set a "neutral" rating and a $196.00 price target on the stock. Leerink Partnrs raised shares of Zoetis to a "strong-buy" rating in a research note on Monday, December 2nd. Finally, JPMorgan Chase & Co. increased their target price on shares of Zoetis from $225.00 to $230.00 and gave the company an "overweight" rating in a report on Friday, October 11th. One analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Zoetis presently has an average rating of "Buy" and an average price target of $211.89.

Zoetis Price Performance

NYSE ZTS traded down $2.22 on Tuesday, hitting $163.68. The stock had a trading volume of 2,488,487 shares, compared to its average volume of 2,415,422. The firm has a 50-day moving average of $173.07 and a 200-day moving average of $180.47. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. Zoetis has a 52-week low of $144.80 and a 52-week high of $200.53. The company has a market capitalization of $73.85 billion, a price-to-earnings ratio of 30.77, a price-to-earnings-growth ratio of 2.91 and a beta of 0.89.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter last year, the business posted $1.36 earnings per share. The firm's revenue was up 11.6% compared to the same quarter last year. Equities analysts expect that Zoetis will post 5.9 EPS for the current year.

Institutional Trading of Zoetis

Large investors have recently modified their holdings of the business. Cherry Creek Investment Advisors Inc. lifted its holdings in Zoetis by 2.0% in the 3rd quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company's stock worth $590,000 after buying an additional 58 shares during the period. Grove Bank & Trust lifted its stake in Zoetis by 0.5% in the third quarter. Grove Bank & Trust now owns 11,763 shares of the company's stock worth $2,298,000 after acquiring an additional 61 shares during the period. Hancock Whitney Corp boosted its holdings in Zoetis by 0.3% in the third quarter. Hancock Whitney Corp now owns 18,569 shares of the company's stock valued at $3,628,000 after acquiring an additional 61 shares in the last quarter. Strategy Asset Managers LLC increased its position in Zoetis by 3.5% during the 3rd quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company's stock valued at $356,000 after purchasing an additional 62 shares during the period. Finally, Edge Capital Group LLC raised its holdings in Zoetis by 3.7% in the 2nd quarter. Edge Capital Group LLC now owns 1,786 shares of the company's stock worth $310,000 after purchasing an additional 64 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.